La Jolla Pharmaceutical Company Announces FDA Acceptance of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
La Jolla Pharmaceutical Company Announces FDA Acceptance of IND for LJPC-501

SAN DIEGO, CA--(Marketwired - Jul 2, 2013) - La Jolla Pharmaceutical Company ( OTCBB : LJPC ) ("La Jolla" and "Company"), announced today that the FDA Division of Cardiovascular and Renal Products has accepted the Company's Investigational New Drug ("IND") application for LJPC-501. La Jolla will start a Phase 1 clinical trial of LJPC-501 in patients with hepatorenal syndrome ("HRS"), Type 1 and Type 2.

"We are excited to bring a second compound into the clinic this year, especially for a disease such as HRS, in which no approved therapies are available," said George Tidmarsh, MD, PhD, President and CEO of La Jolla. "La Jolla is committed to providing therapies for patients with life-threatening diseases, and the approval of our IND for LJPC-501 is an important step in the process toward meeting this goal."

La Jolla plans to initiate a Phase 1 trial in HRS in the third quarter. For additional information on this study, please visit www.ljpc.com .

About Hepatorenal Syndrome

HRS is a life-threatening form of progressive renal failure in patients with liver cirrhosis. In these patients, the diseased liver secretes vasodilator substances (e.g., nitric oxide and prostaglandins) into the bloodstream that cause under-filling of blood vessels. This low blood pressure state causes a reduction in blood flow to the kidneys. As a means to restore systemic blood pressure, the kidneys induce both sodium and water retention, which contribute to ascites, a major complication associated with HRS.

About LJPC-501

LJPC-501 is a peptide agonist of the renin-angiotensin system that acts to help the kidneys balance body fluids and electrolytes. Studies suggest that LJPC-501 may improve renal function in patients with HRS. The Company has filed a patent covering LJPC-501 in renal failure and believes that Type 1 HRS may be an orphan disease amenable to orphan designation from FDA. 

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company dedicated to the development of medical treatments that significantly improve outcomes in patients with life-threatening diseases. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. For more information on the Company please visit http://www.ljpc.com .

Forward Looking Statement Safe Harbor

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause actual results to be materially different from these forward-looking statements. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings from time to time with the U.S. Securities and Exchange Commission ("SEC"), all of which are available free of charge on the SEC's web site http://www.sec.gov . These risks include, but are not limited to, risks relating to the development of GCS-100 and LJPC-501, the success and timing of future preclinical and clinical studies of this compound, and potential indications for which GCS-100 and LJPC-501 may be developed. Subsequent written and oral forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in the Company's reports filed with the SEC. The Company expressly disclaims any intent to update any forward-looking statements.

Company Contact George F. Tidmarsh, M.D., Ph.D. President & Chief Executive Officer La Jolla Pharmaceutical Company Phone: (858) 207-4264 Email: GTidmarsh@ljpc.com And Chester S. Zygmont, III Director of Finance La Jolla Pharmaceutical Company Phone: (858) 207-4262 Email: czygmont@ljpc.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 110

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
LNG’s Coming Glut Could Gut Global Trading Profits

Updated Category News Views 33

A five-year LNG surplus is the sort of forecast that makes people nod politely today and panic much too late. Bain & Company is putting a hard edge on that risk: the global trading profit pool could slide from an estimated $20 billion in 2026 to roughly $5.5 billion a year during a 2030–34 glut, then potentially tip below zero once cancellation costs bite. That is not a...

Continue Reading
24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 126

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading
Discount Tire’s $10 Correction Matters This Black Friday

Updated Category News Views 72

A ten-dollar correction is not a catastrophe, but it is precisely the sort of loose screw that deserves a glance before Black Friday shouting gets underway. Discount Tire says an earlier version of its Nov. 17, 2026 promotion release listed combined instant savings of $390 when the correct maximum is $380. The company issued the correction and supplied a revised release....

Continue Reading
Vizsla's Panuco Delay Puts Security Ahead of Speed

Updated Category News Views 34

A mine schedule can absorb a calendar slip; the people around a mine cannot be treated like a line item. Vizsla Silver's update on Panuco is therefore not the usual development-company chest thumping. It is a sober admission that security, permitting and site readiness have pushed first silver to the second half of 2028, one year later than the prior H2 2027 target....

Continue Reading
Automotive Laminates: Small Market, Real EV Leverage

Updated Category News Views 0

Cabin trim has become a surprisingly serious battleground, and that is the whole point of this automotive laminates story. Nobody buys a vehicle because somebody bragged about a multilayer film behind the door panel. Yet the materials under the fingertips, beneath the carpet, and around the dashboard increasingly decide whether an interior feels cheap, quiet, durable, or...

Continue Reading
Shenzhen’s APEC Moment Puts Pacific Trade Links in Focus

Updated Category News Views 80

A city that once logged eight stock trades in a day is hosting APEC with a very different kind of ledger in view. Shenzhen Stock Exchange began trial operations on December 1, 1990 with one stock, eight trades and roughly 200,000 yuan in turnover. By the end of September 2026, it had 2,908 listed companies and about 42.43 trillion yuan in combined market value. That is...

Continue Reading
American Pride Bank Tests a Fast Southeast Expansion

Updated Category News Views 154

Those old Winston-Salem smokestacks make a fitting backdrop for a bank trying to build something new, and American Pride Bank is moving with uncommon speed. Its new office at 450 N. Patterson Ave., Suite 200 sits in the Bailey South building in Innovation Quarter, across from Bailey Park and amid a district deliberately remade for founders, researchers and growing...

Continue Reading
Markley’s Lowell Campus Turns Data Land Into Arboretum

Updated Category News Views 203

Server halls rarely get credited with restoring a landscape, which is why Markley’s Lowell campus caught my eye. On November 18, 2026, the company said its Lowell data center campus had earned Level I arboretum accreditation from the ArbNet Arboretum Accreditation Program. ArbNet describes itself as the only international accreditation program specifically for arboreta,...

Continue Reading
2027 Auto Brand Awards Put Long-Term Buyer Value First Again

Updated Category News Views 32

Car shoppers staring down high prices and financing costs do not need another shiny badge; they need some help separating durable value from showroom wallpaper. That is why the 2027 U.S. News vehicle brand awards, announced Nov. 19, 2026, are worth a look. They are not a sales forecast, not a profit forecast, and certainly not a reason to blindly crown a corporate winner....

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating Trailblazers: Equity Prime Mortgage’s TAG 2025 Awards

Updated Category News Views 146

Recognizing Industry Innovators at TAG 2025 Awards spotlight collaboration, innovation, and empowerment shaping the next era of mortgage leadership. Equity Prime Mortgage (EPM), a prominent independent mortgage lender, has unveiled the winners of The American Gift (TAG) 2025 awards, honoring rising stars and leaders in the mortgage industry. During the event, founder and...

Continue Reading
GDS Holdings Set to Announce Q1 2025 Financial Performance

Updated Category News Views 144

GDS Holdings to Announce its First Quarter 2025 Financial Results GDS Holdings Limited, a prominent player in high-performance data center development and operations, is gearing up to share its financial performance for the first quarter of 2025. The announcement is expected to take place shortly before the opening of the U.S. market on May 20, 2025. As an investor and...

Continue Reading
Vineyard Workforce Insights: Skills and Opportunities Ahead

Updated Category News Views 152

Understanding the Vineyard Workforce A groundbreaking survey into the vineyard workforce has been conducted, collecting responses from nearly 1,700 workers. This survey stands as the most extensive study of its kind, yielding fascinating insights into job satisfaction, career aspirations, and the financial landscape of vineyard employees. Insight into Job Satisfaction...

Continue Reading
Explore the New Trading Opportunities with IDEX Biometrics

Updated Category News Views 126

Exciting Developments for IDEX Biometrics ASA Investors Recent efforts by IDEX Biometrics ASA have resulted in noteworthy advancements for its investors. With a strategic focus on growth and innovation, the company has successfully completed a private placement followed by a subsequent offering, significantly enhancing its financial posture. Overview of the Private...

Continue Reading
Celebrate Organic Month with Natural Grocers' Exciting Offers

Updated Category News Views 56

Celebrate Organic Month at Natural Grocers This September This September, Natural Grocers invites everyone to join in the festivities of Organic Month, featuring fantastic discounts, educational programs, and opportunities for fundraising. From September 12 to 14, customers can enjoy three days filled with amazing savings, samples, and freebies, making it the ideal time...

Continue Reading